After a year of holding the option to acquire Millipede, Boston Scientific decided to do it a year before the option ran out. When the pair signed the agreement last January, Boston Scientific paid $90 million for a portion of the mitral regurgitation startup’s shares. Now, Boston Scientific is spending $325 million

Now that everyone has said yes, Boston Scientific has gone to the banks to sign a number of new lending agreements, including a large credit facility it could use to finance its $4.2 billion acquisition offer for British medical device maker BTG plc. The information, which came from recently posted

Boston Scientific has reached an agreement on the terms of a recommended offer to acquire BTG plc., a United Kingdom-based company that develops and commercializes products used in minimally-invasive procedures, targeting vascular diseases and cancer, as well as acute care pharmaceuticals. Under the terms of the transaction, holders of BTG’s

Stryker has made a quiet offer to acquire its rival Boston Scientific, which would create a behemoth with $21.5 billion in annual sales through one of the largest medical device deals on record, according to a report from the Wall Street Journal. The combined company could tout up to 62,000 employees and

    Boston Scientific has reached an agreement on the terms of a recommended offer to acquire BTG plc., a United Kingdom-based company that develops and commercializes products used in minimally-invasive procedures, targeting vascular diseases and cancer, as well as acute care pharmaceuticals. Under the terms of the transaction, holders